FDA Requests More Restrictions on Ovarian Cancer Drugs
The limits on second-line prescribing for one of the drugs, rucaparib, could put the company's financial future at risk, a company report shows.
Medscape Medical News
source https://www.medscape.com/viewarticle/984547?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/984547?src=rss
Comments
Post a Comment